<?xml version="1.0" encoding="UTF-8"?>
<p id="para30">Initial findings for convalescent plasma therapy for the treatment of COVID-19 are encouraging but have so far only come from two small studies done in China; a 
 <ext-link ext-link-type="uri" xlink:href="https://jamanetwork.com/journals/jama/fullarticle/2763983" id="interrefs40" xmlns:xlink="http://www.w3.org/1999/xlink">case series of five patients</ext-link> with critical COVID-19 receiving mechanical ventilation, and a 
 <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/content/early/2020/04/02/2004168117" id="interrefs50" xmlns:xlink="http://www.w3.org/1999/xlink">pilot study done in ten patients</ext-link> with severe COVID-19. In both studies, convalescent plasma therapy was shown to be safe and clinical outcomes improved, including fever, Sequential Organ Failure Assessment score, and respiratory symptoms, in some cases within 1â€“3 days of treatment. The 
 <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/revised-information-investigational-covid-19-convalescent-plasma" id="interrefs60" xmlns:xlink="http://www.w3.org/1999/xlink">US Food and Drug Administration (FDA) has approved</ext-link> the use of convalescent plasma under compassionate use rules, but randomised controlled trials are now needed to provide clinical evidence. Three trials initiated by the 
 <ext-link ext-link-type="uri" xlink:href="https://ccpp19.org/index.html" id="interrefs70" xmlns:xlink="http://www.w3.org/1999/xlink">US National COVID-19 Convalescent Plasma Project</ext-link> are currently being evaluated by the FDA to test the activity and safety of convalescent plasma in three groups of patients: people who have been exposed to the virus and are at high risk of developing severe COVID-19 (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04323800" id="interrefs80" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04323800</ext-link>); hospitalised patients with acute respiratory symptoms (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04325672" id="interrefs90" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04325672</ext-link>); and patients with severe COVID-19 who are mechanically ventilated. Other trials are also planned or underway in China, Colombia, Iran, Mexico, and the Netherlands.
</p>
